Registry for Alzheimer's Disease Treatments and Diagnostics
Alzheimer's National Registry for Treatment and Diagnostics
Alzheimer's Disease and Related Disorders Association, Inc · NCT06170268
This study is collecting health information from people with Alzheimer's who are trying new approved treatments to see how well they work in real life.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Alzheimer's Disease and Related Disorders Association, Inc (other) |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT06170268 on ClinicalTrials.gov |
What this trial studies
The Alzheimer's National Registry for Treatment and Diagnostics (ALZ-NET) collects long-term clinical and safety data from patients being evaluated for or treated with novel FDA-approved therapies for Alzheimer's disease. This observational registry aims to track health outcomes in a real-world setting, adapting as new treatments are approved. It focuses on gathering comprehensive data, including cognitive measures and biomarkers, to enhance understanding and improve clinical care delivery. The initiative encourages collaboration and information sharing among clinical and research communities.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older diagnosed with mild cognitive impairment or dementia with a suspicion of Alzheimer's disease who are being evaluated for or receiving novel FDA-approved treatments.
Not a fit: Patients who do not have a diagnosis of Alzheimer's disease or related conditions, or those not receiving FDA-approved treatments, may not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could provide valuable insights into the long-term effectiveness and safety of new Alzheimer's treatments, ultimately improving patient care.
How similar studies have performed: Other observational registries have shown success in tracking treatment outcomes for chronic diseases, suggesting that this approach could be beneficial for Alzheimer's disease as well.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient or patient's legally authorized representative (LAR) or proxy (e.g., spouse or legal guardian) has the ability to understand the purpose and risks of ALZ-NET and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local patient privacy regulations. * Patient is at least 18 years of age at the time of informed consent. * Patient has a diagnosis of MCI or dementia with clinical suspicion of AD as contributing pathology and (1) is being evaluated for treatment or, (2) will be initiating treatment, or (3) has already initiated treatment with novel FDA-approved AD therapies in real-world clinical practice. * If treatment is initiated at the time of consent, patient meets appropriate label requirements and treatment follows appropriate use recommendations for novel FDA-approved AD therapy/therapies. * Patient's treating clinician has made the decision to provide clinical care or treatment prior to patient consent and independently of the purpose of ALZ-NET.
Where this trial is running
Chicago, Illinois
- Full List of Active Sites — Chicago, Illinois, United States (RECRUITING)
Study contacts
- Principal investigator: Gil Rabinovici, MD — University of California, San Francisco
- Study coordinator: ALZ-NET Operations Team
- Email: alz-net@acr.org
- Phone: 215-574-3181
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Alzheimer Disease, Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases